APA (7th ed.) Citation

Masahiko Iwamoto, Tetsuya Kubota, Yoshitaka Sakurai, Nobuhiro Wada, Seiji Shioda, Toshimasa Yamauchi, . . . Naoto Kubota. (2022). The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes. Wiley.

Chicago Style (17th ed.) Citation

Masahiko Iwamoto, Tetsuya Kubota, Yoshitaka Sakurai, Nobuhiro Wada, Seiji Shioda, Toshimasa Yamauchi, Takashi Kadowaki, and Naoto Kubota. The Sodium‐glucose Co‐transporter 2 Inhibitor Tofogliflozin Suppresses Atherosclerosis Through Glucose Lowering in ApoE‐deficient Mice with Streptozotocin‐induced Diabetes. Wiley, 2022.

MLA (9th ed.) Citation

Masahiko Iwamoto, et al. The Sodium‐glucose Co‐transporter 2 Inhibitor Tofogliflozin Suppresses Atherosclerosis Through Glucose Lowering in ApoE‐deficient Mice with Streptozotocin‐induced Diabetes. Wiley, 2022.